Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: lamivudine

« Back to Dashboard
Lamivudine is the generic ingredient in six branded drugs marketed by Viiv Hlthcare, Glaxosmithkline, Silarx Pharms Inc, Apotex, Apotex Inc, Aurobindo Pharma Ltd, Hetero Labs Ltd V, Lupin Ltd, Mylan Pharms Inc, Merck Sharp Dohme, and Teva Pharms, and is included in nineteen NDAs. There are eight patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

This ingredient has thirty-nine patent family members in twenty-seven countries.

There are twenty-four drug master file entries for lamivudine. Nine suppliers are listed for this compound. There are sixty tentative approvals for this compound.

Summary for Generic Name: lamivudine

Tradenames:6
Patents:8
Applicants:11
NDAs:19
Drug Master File Entries: see list24
Suppliers: see list9
Therapeutic Class:Antivirals
Formulation / Manufacturing:see details

Tentative approvals for LAMIVUDINE

Applicant Application No. Form Dosage
<disabled><disabled>TABLET; ORAL150MG; 300MG; 200MG
<disabled><disabled>TABLET; ORAL150MG; 300MG; 200MG
<disabled><disabled>TABLET; ORAL150MG; 300MG; 600MG

Clinical Trials for: lamivudine

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lupin Ltd
LAMIVUDINE AND ZIDOVUDINE
lamivudine; zidovudine
TABLET;ORAL090246-001May 15, 2012RXNo<disabled><disabled>
Lupin Ltd
LAMIVUDINE
lamivudine
TABLET;ORAL205217-001Dec 18, 2014RXNo<disabled><disabled>
Aurobindo Pharma Ltd
LAMIVUDINE AND ZIDOVUDINE
lamivudine; zidovudine
TABLET;ORAL202418-001May 15, 2012RXNo<disabled><disabled>
Hetero Labs Ltd V
LAMIVUDINE
lamivudine
TABLET;ORAL203260-001Jan 2, 2014RXNo<disabled><disabled>
Aurobindo Pharma Ltd
LAMIVUDINE
lamivudine
TABLET;ORAL202032-001Nov 17, 2011RXNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: lamivudine

Country Document Number Publication Date
African Regional IP Organization (ARIPO)300Jan 20, 1994
Spain2171158Sep 01, 2002
United Kingdom9111902Jul 24, 1991
New Zealand242981Apr 27, 1994
Portugal517145Jul 31, 2002
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc